Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

Author(s): Michael C. Heinrich

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 4 , Issue 3 , 2004

Become EABM
Become Reviewer
Call for Editor


Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

Keywords: flt3, tyrosine kinase, kinase inhibitor, aml, pdgfr

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [255 - 271]
Pages: 17
DOI: 10.2174/1389557043487394
Price: $65

Article Metrics

PDF: 4